How to access Farxiga from India — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Indian patient with type 2 diabetes, heart failure (reduced or preserved ejection fraction), or chronic kidney disease may receive a prescription for Farxiga (dapagliflozin) from their treating cardiologist, nephrologist, or endocrinologist. Farxiga is FDA-approved across these cardiometabolic indications and developed by AstraZeneca. Dapagliflozin is registered and broadly available in India under the Forxiga brand and several generic labels, but specific branded presentations, dose strengths, or the US-labelled product may not be reliably stocked — this guide addresses access where your physician has specified the US-labelled Farxiga product for a particular clinical reason (for example a specific heart-failure or CKD indication workup, or formulary-gap at a tertiary institution).
This guide explains the pathway, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Farxiga is an oral SGLT2 inhibitor taken once daily at 5 mg or 10 mg. Indications span T2D glycaemic control, cardiovascular risk reduction in adults with T2D, heart failure (HFrEF and HFpEF) regardless of diabetes status, and chronic kidney disease. Eligibility is based on the specific indication, with appropriate exclusions (low eGFR thresholds vary by indication; genital mycotic infection and euglycaemic DKA risk counselling).
Is Farxiga legally importable into India?
Yes — through the CDSCO / Drugs Controller General of India (DCGI) personal-use and hospital-sponsored named-patient import frameworks. The mechanism permits a registered medical practitioner (or the patient on personal-use grounds with physician documentation) to request import of an FDA-approved medicine where the locally available supply does not meet the specific clinical need — for example a US-labelled presentation, a specific dose strength, or institutional formulary-gap scenarios.
How the pathway works, step by step
- Consultation with your treating specialist. Documentation of specific indication, comorbidity profile, and clinical rationale (including the reason for US-labelled product where relevant).
- Baseline assessment. HbA1c, eGFR, volume status, and heart-failure or CKD workup as indicated.
- CDSCO personal-use / named-patient application. The physician or hospital files clinical rationale, patient identification, product details, and strength.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Farxiga from authorised distribution under DSCSA.
- Ambient shipment. Farxiga ships under controlled ambient conditions with chain-of-custody documentation and customs clearance support.
- Arrival and dispensing. The hospital pharmacy or licensed personal-use receiver releases the bottle to the patient.
What documentation your physician needs
- Clinical rationale letter confirming specific indication and Farxiga as the indicated therapy (with rationale for US product where relevant)
- Verification of Indian medical registration (NMC)
- Baseline HbA1c, eGFR, and heart-failure or CKD workup as indicated
- Patient identifier and address for the import record
- Planned dosing strength (5 mg or 10 mg) and monitoring plan
Reserve Meds provides a physician documentation kit bundling templates CDSCO reviewers and Indian customs expect for cardiometabolic named-patient and personal-use imports.
Costs and timing
Farxiga's US cash-pay reference cost sits in an indicative 2026 annual range of roughly USD 6,000–7,000 for continuous daily dosing. Note that locally registered dapagliflozin in India is materially less expensive through the local pharmacy channel — US product import is typically reserved for specific clinical or institutional reasons. International logistics, customs clearance, CDSCO documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. These figures are indicative, not guaranteed.
Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 14–28 days from the moment a complete application is submitted and customs processing begins.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
- Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and CDSCO / customs review.
- Logistics. Ambient-controlled shipment with customs clearance support.
- Concierge case lead. A named point of contact coordinating refills.
What we do not do: We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating physician. We operate on a waitlist basis during pre-launch.
Frequently asked
Locally registered dapagliflozin is available — why import? Most Indian patients are best served by the locally registered product. Reserve Meds is relevant only where your physician has a specific clinical or institutional reason to prescribe US-labelled Farxiga.
Is Farxiga safe for non-diabetic heart failure patients? FDA labeling covers HFrEF and HFpEF regardless of diabetes status. Your cardiologist establishes eligibility per the specific indication.
What monitoring does SGLT2 therapy require? Renal function, volume status, foot exams in diabetics, attention to euglycaemic DKA risk — your physician sets the full cadence.
Will insurance cover this? Cash-pay is the default. Some Indian private insurers and diaspora policies consider case by case; we supply documentation but do not process claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Farxiga coordination.
Add me to the Farxiga waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.